Compass Therapeutics' immuno-oncology prospect clears solid tumors in mice

The expression of CD137 on immune cells has made the protein receptor an attractive target in the development of new cancer immunotherapy drugs. Now, Compass Therapeutics has preclinical data showing that its CD137 agonist, CTX-471, could work safely in solid tumors, and it's advancing the drug into phase 1 human trials.

Compass Therapeutics' immuno-oncology prospect clears solid tumors in mice
The expression of CD137 on immune cells has made the protein receptor an attractive target in the development of new cancer immunotherapy drugs. Now, Compass Therapeutics has preclinical data showing that its CD137 agonist, CTX-471, could work safely in solid tumors, and it's advancing the drug into phase 1 human trials.